Loading stock data…
JSPR
$0.47-0.00 (-0.43%)
After Hours$0.45-0.02 (-3.43%)· Last close Jun 9
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Jasper Therapeutics, Inc. in the Healthcare sector is trading at $0.47. Wall Street consensus targets $7.50 (5 analysts), implying a +1509.4% move over the next 12 months. The stock is currently near its 52-week low of $0.42, remaining 71.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +1509.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 20) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.47
Potential Downside
0%
Whystock Fair Value$0.47
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$7.50+1509.4%
Range$1.50 – $20.00
Fundamentals
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1639.24%
Volume
Today's trading volume
404,549
Recent News
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now
Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the 8 Most Oversold Penny Stocks to Buy Right Now. On April 1, 2026, Evercore ISI lowered the price target on Jasper Therapeutics, Inc. (NASDAQ:JSPR) to $7 from $12 and maintained an Outperform rating. Evercore ISI said the adjustment reflects updates across its small-to-mid cap biotechnology coverage as […]
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the penny stocks with the potential to rise 1000 percent. UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a $1.50 price target, arguing that competition in the space could limit upside. The note also said investors likely want to see longer-term […]
Jasper Therapeutics reports updated data from briquilimab studies
Jasper Therapeutics (JSPR) is reporting positive updated clinical data from Jasper’s BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU, as well as from the open label extension study in CSU and CIndU. Treatment with briquilimab resulted in rapid disease control in the additional participants enrolled in the 240mg / 180mg Q8W cohort in the BEACON study, with 83% of participants achieving a complete response by week 3 after the initial 240mg dose, and 67% reportin
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...